June 2025 has proven to be a landmark month for cell therapy, with 14 major developments spanning multiple therapeutic areas and representing significant progress in treating some of medicine’s most challenging conditions. From groundbreaking diabetes treatments that eliminate the need for insulin to innovative CAR-T therapies targeting brain tumors, this month’s advances signal a new era of precision medicine becoming reality.
The developments encompass five key areas: CAR-T therapy innovations, transformative diabetes treatments, pioneering stem cell applications, revolutionary gene therapy breakthroughs, and crucial regulatory advances that are accelerating patient access to these life-changing treatments.
1. CAR-T Therapy: Leading the Charge Against Cancer
1.1. Regulatory Milestone: FDA Removes REMS Requirements
In a groundbreaking regulatory decision on June 27, 2025, the FDA announced the removal of Risk Evaluation and Mitigation Strategies (REMS) requirements for six approved CAR-T cell therapies1. This decision affects major treatments including Bristol Myers Squibb’s idecabtagene vicleucel (Abecma) and lisocabtagene maraleucel (Breyanzi), Janssen’s ciltacabtagene autoleucel (Carvykti), Novartis’s tisagenlecleucel (Kymriah), and Kite Pharma’s brexucabtagene autoleucel (Tecartus) and axicabtagene ciloleucel (Yescarta). This regulatory shift represents a major advancement for patient access, as hospitals and clinics providing these therapies no longer require specific certification, and centers are no longer mandated to have tocilizumab immediately accessible on-site. The decision reflects growing confidence in the safety profile of these therapies and the healthcare system’s improved ability to manage associated toxicities.
1.2. Breakthrough in Brain Cancer Treatment
University of Pennsylvania researchers presented remarkable results for their dual-target CAR-T therapy approach against glioblastoma, one of the most aggressive brain cancers2. Published simultaneously in Nature Medicine and presented at the 2025 ASCO Annual Meeting, the study showed that 62% of patients experienced tumor reduction following treatment with CAR-T cells targeting both EGFR and IL13Rα2 proteins. The therapy, administered directly into the cerebrospinal fluid, demonstrated unprecedented results in a notoriously difficult-to-treat cancer. While most patients experienced tumor regrowth after one to three months, encouraging long-term signals emerged: two patients remained alive with stable disease beyond six months, and among seven patients with at least 12 months of follow-up, 43% were still alive after a year—a remarkable achievement given that typical survival for recurrent glioblastoma ranges from 6 to 10 months.
1.3. Long-Term Success in Multiple Myeloma
Five-year follow-up data from the cilta-cel (Carvykti) clinical trials revealed extraordinary durability in multiple myeloma treatment3. Of 97 patients with advanced, end-stage multiple myeloma who received this CAR-T therapy, 32 patients (33%) remain completely cancer-free five years after a single infusion. This represents a potential paradigm shift from treating multiple myeloma as a progressive, ultimately fatal disease to viewing it as a potentially curable condition.
1.4. Johnson & Johnson’s Dual-Targeting Innovation
Johnson & Johnson’s investigational dual-targeting CAR-T therapy JNJ-4496 showed impressive early results in large B-cell lymphoma4. Presented at the 2025 European Hematology Association Congress, the Phase 1b study demonstrated a 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose. The therapy uniquely targets both CD19 and CD20 antigens, potentially addressing common resistance mechanisms in relapsed or refractory disease.
Major cell therapy developments by category in June 2025, showing CAR-T therapy leading with 4 developments, followed by gene therapy and stem cell therapy with 3 each
2. Diabetes Cell Therapy: Approaching a Functional Cure
2.1. Vertex’s Zimislecel: Achieving Insulin Independence
June 2025 witnessed a potential breakthrough in Type 1 diabetes treatment with Vertex Pharmaceuticals’ zimislecel therapy results5. The therapy utilizes stem cells converted into islet cells in laboratory settings, which are then infused into patients where they migrate to the liver and begin producing insulin. The results from this Phase 1/2 FORWARD study, featured in the American Diabetes Association (ADA) annual conference in Chicago, demonstrated that all 12 participants:
a) demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up,
b) achieved the ADA targets of HbA1c <7% and time in range of >70%,
c) were free of severe hypoglycaemic events (SHEs) from day 90 onwards,
d) had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%), and
e) 10/12 (83%) no longer required exogenous insulin at month 12.
These allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection6.
2.2. Sana Biotechnology’s Immune-Evasive Innovation
Sana Biotechnology reported a historic first on June 23, 2025: the successful transplantation of engineered islets that produce insulin without requiring immunosuppressive drugs7. Presented in the 85th Annual American Diabetes Association (ADA) Scientific Sessions, Sana announced positive six-month results from a first-in-human study transplanting hypoimmune (HIP)-engineered islet cells into a type 1 diabetes patient without immunosuppression. The transplanted cells survived, evaded immune detection, and produced insulin, as shown by increased C-peptide levels and MRI evidence of graft survival. No safety issues were observed. This breakthrough suggests the potential for a functional cure for type 1 diabetes without lifelong insulin or immunosuppression. Sana is applying this technology to develop SC451, a stem cell-derived therapy aiming for normal blood glucose without insulin injections.
3. Stem Cell Therapy: Expanding Therapeutic Horizons
3.1. European Approval for Blood Cancer Treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional marketing authorization for Zemcelpro (dorocubicel) on June 20, 20258. This allogeneic stem cell therapy derived from umbilical cord blood provides a crucial option for patients with blood cancers who need stem cell transplants but have no suitable donors following myeloablative conditioning. Zemcelpro contains both expanded CD34+ cells and non-expanded CD34- cells from umbilical cord blood. Once infused to the patient, the cells from Zemcelpro migrate to the bone marrow where they divide, mature and differentiate in all hematological cell lineages. By increasing the number of available cells, the therapy makes stem cells from small cord blood units more effective, potentially addressing the cell count limitations that have historically restricted cord blood transplantation.
3.2. Neurological Applications: Parkinson’s and Epilepsy
Aspen Neuroscience presented six-month safety and efficacy data for their autologous iPSC-derived dopaminergic neuronal precursor cell therapy (ANPD001) for Parkinson’s disease at the International Society for Stem Cell Research 2025 Annual Meeting9. The first-of-its-kind study showed clinician-reported improvements averaging 45% and patient-reported improvements averaging 71%, with a strong safety profile and notably no immunosuppression required.
Neurona Therapeutics achieved a significant milestone by dosing the first patient in their Phase 1/2 clinical trial of NRTX-1001 for bilateral drug-resistant epilepsy10. This represents the first stem cell therapy trial specifically targeting epilepsy affecting both sides of the brain, addressing a patient population with extremely limited treatment options. This milestone followed announcement of its unilateral drug-resistant epilepsy trial results in April, that included:
a) a 92% median reduction from baseline in disabling seizures during the 7-12-month efficacy endpoint period,
b) an 80% (4/5) responder rate with >75% seizure reduction at the 12-month endpoint, and
c) durable seizure control in all (4/4) responders followed for 18-24 months after a single low-dose of NRTX-1001 (Cohort 1).
All patients (5/5) in Cohort 1 had significantly improved quality-of-life test scores, with no patient to date experiencing persistent decline in cognition and no adverse events to date.
Distribution of cell therapy developments across different therapeutic areas in June 2025, with blood cancers leading at 36% (5 developments), followed by neurological disorders at 21% (3 developments)
4. Gene Therapy: Precision Medicine Becomes Reality
4.1. First Personalized CRISPR Success
Perhaps the most remarkable development of June 2025 was the successful treatment of baby KJ with the first personalized CRISPR gene editing therapy11,12. The seven-month-old infant was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency—a rare, life-threatening genetic disorder that prevents the liver from fully breaking down protein byproducts, causing toxic levels of ammonia accumulation. He received a custom base editing treatment developed specifically for his unique mutation.
The achievement represents a stunning collaboration between multiple teams from academia and industry, going from genetic sequence identification to treatment delivery in less than seven months. The therapy used base editing, a form of gene editing that replaces single DNA letters without breaking the DNA strand, delivered via lipid nanoparticles. Now nine months old, baby KJ appears healthy, marking a historic milestone in precision medicine.
4.2. Platform Designations and Pipeline Advances
Sarepta Therapeutics received FDA platform technology designation for their rAAVrh74 viral vector used in bidridistrogene xeboparvovec (SRP-9003)13. This designation recognizes the reproducibility and adaptability of the technology across multiple therapeutic programs, potentially accelerating development timelines for future gene therapies using this platform.
uniQure announced alignment with the FDA for their Huntington’s disease gene therapy AMT-130, positioning the company for a potential Biologics License Application filing in Q1 202614,15. AMT-130 consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene (HTT), and potentially inhibit the production of the mutant protein (mHTT). If successful, this could represent the first gene therapy approved for Huntington’s disease.
5. Regulatory and Infrastructure Developments
5.1. FDA START Program Success
The FDA’s Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program demonstrated significant success in accelerating development timelines16,17. Companies including Neurogene, Moderna, and Myrtelle reported development timeline reductions of several years through the program’s scheduled meeting cadences, timely responses, and collaborative problem-solving approach.
5.2. Enhanced Oversight and Manufacturing
The FDA announced enhanced oversight of clinical trials involving the export of American citizens’ cells to foreign laboratories for genetic engineering18. This decision, announced June 18, 2025, reflects growing concerns about genetic engineering procedures conducted in countries considered hostile to U.S. interests, often without patients’ knowledge or consent.
Modern cell therapy manufacturing cleanroom with scientists working in sterile conditions
6. Global Impact and Future Outlook
The developments of June 2025 span the globe, with significant contributions from American institutions like the University of Pennsylvania and Children’s Hospital of Philadelphia, European regulatory advances through the EMA, and international collaborations driving innovation forward.
These advances collectively address some of medicine’s most challenging conditions across seven major therapeutic areas, from blood cancers affecting millions worldwide to rare genetic diseases affecting only hundreds of patients globally. The diversity of approaches—from CAR-T cells and stem cell therapies to precision gene editing—demonstrates the maturation of the cell therapy field.
7. Conclusion: A New Era of Cellular Medicine
June 2025 will be remembered as one of the pivotal months in the evolution of cell therapy. The removal of regulatory barriers, achievement of functional cures for diabetes, breakthroughs in treating aggressive brain cancers, and the first successful personalized gene editing therapy collectively signal that cellular medicine has moved from experimental promise to clinical reality.
As we move forward, the success of these therapies will depend not only on continued scientific innovation but also on developing scalable manufacturing processes, ensuring equitable access, and maintaining the highest safety standards. The 14 major developments documented this month provide a roadmap for the future of medicine—one where diseases once considered untreatable become manageable, and where precision medicine becomes accessible to patients worldwide.
The cell therapy revolution is no longer coming; it has arrived, and June 2025 has proven to be one of its defining moments.